NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it has acquired the biomarker services division of PPD, a contract research firm focused on pharmaceutical services based in Wilmington, NC, for an undisclosed sum.

Montreal-based Caprion said that it closed the acquisition of PPD Biomarker Discovery Services on December 31, 2009.

Caprion said that it will fulfill PPD’s existing contractual biomarker obligations from its Montreal facilities and from a new US facility to be called Caprion Proteomics, US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.